CCI order investigation against Becton Dickinson

For indulging in unfair practices for printing higher MRP for hospitals and lower for open market


The Commission has ordered a detailed probe by its investigation arm DG

Competition Commission of India (CCI) has ordered an investigation against Becton Dickinson India for alleged anti-competitive practices with respect to healthcare services.

Becton Dickinson, an MNC that makes disposable syringe under the brand name 'Emerald', has been accused for selling disposable syringe on higher MRP to hospitals and sell same product with lower price in open market.

The Commission has ordered a detailed probe by its investigation arm Director General (DG) after finding "prima facie" case of contravening competition norms.

According to the Commission, the informant is primarily aggrieved by the conduct of the opposite parties in charging a higher MRP for disposable syringe manufactured by Becton Dickinson India (OP 1) and brought from an in house pharmacy located within the hospital network of Max Super Speciality Hospital (OP 2).

The price was found to be higher compared to MRP (Maximum Retail Price) of the same product in the open market.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email